Induction of fibronectin by HER2 overexpression triggers adhesion and invasion of breast cancer cells

被引:37
|
作者
Jeon, Myeongjin [1 ,2 ]
Lee, Jeongmin [1 ]
Nam, S. J. [1 ]
Shin, Incheol [3 ]
Lee, J. E. [1 ,2 ]
Kim, Sangmin [1 ]
机构
[1] Samsung Med Ctr, Dept Surg, Seoul 135710, South Korea
[2] Sungkyunkwan Univ, Samsung Adv Inst Hlth Sci & Technol, Dept Hlth Sci & Technol, Seoul 135710, South Korea
[3] Hanyang Univ, Dept Life Sci, Seoul 133791, South Korea
关键词
Fibronectin; HER2; Trastuzumab; Adhesion; Invasion; MESENCHYMAL TRANSITION; ADJUVANT CHEMOTHERAPY; EXPRESSION; TRASTUZUMAB; KINASE; GROWTH; EGF; ONCOGENE; THERAPY; PATHWAY;
D O I
10.1016/j.yexcr.2015.02.019
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Fibronectin (FN), an extracellular matrix ligand, plays a pivotal role in cell adhesion, migration, and oncogenic transformation. Aberrant FN expression is associated with poor prognoses in various types of cancer, including breast cancer. In the current study, we investigated the relationship between FN induction and HER2 expression in breast cancer cells. Our results showed that the level of FN expression increased in response to HER family ligands, EGF and TGF-alpha in a time- and dose-dependent manner. On the other hand, EGF-induced FN expression decreased in response to trastuzumab, which is a HER2-targeted monoclonal antibody. However, EGF-induced FN expression was not affected by trastuzumab in JIMT-1 breast cancer cells, which are trastuzumab insensitive cells. Next, we introduced the HER2 gene into MDA-MB231 cells to verify the relationship between FN and HER2. The level of FN expression significantly increased in HER2-overexpressed MDA-MB231 cells. In contrast, the induction of FN by HER2 was significantly decreased in response to trastuzumab treatment. In addition, the induction of FN by HER2 was down-regulated by the MEK 1/2 specific inhibitor, U0126. Using conditioned culture media of vec- and HER2-overexpressed MDA-MB231 cells, we observed the cell morphology, adhesion, and invasion of MDA-MB231 cells. Interestingly, in conditioned culture media of HER2-overexpressed MDA-MB231 cells, the cell morphology was altered, and adhesion and invasion of MDA-MB231 cells significantly increased. In addition, our results showed that recombinant human FN augmented cell adhesion and invasion of MDA-MB231 cells while these inductions decreased in response to an FN inhibitor. Therefore, we demonstrated that the induction of FN by HER2 triggers cell adhesion and invasion capacities. (C) 2015 Elsevier Inc. All rights reserved.
引用
收藏
页码:116 / 126
页数:11
相关论文
共 50 条
  • [1] Dicer initiates HER2 overexpression in breast cancer, expanding the indications for trastuzumab
    Zhang, Xiaoyun
    Zhang, Xi
    Wu, Jianhua
    Zhang, Jingjing
    Zhang, Zhe
    Sha, Ziyue
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2024, 17 (09):
  • [2] Synergistic disruption of ERα/HER2 crosstalk by endoxifen and lapatinib in breast cancer cells
    Chan, James Chun Yip
    Ong, Pei Shi
    Lim, Peirong
    Teng, Preben Xiang Long
    Chan, Eric Chun Yong
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 79 (01) : 117 - 130
  • [3] Co-overexpression of HER2/HER3 is a predictor of impaired survival in breast cancer patients
    Berghoff, Anna S.
    Bartsch, Rupert
    Preusser, Matthias
    Ricken, Gerda
    Steger, Guenther G.
    Bago-Horvath, Zsuzsanna
    Rudas, Margareta
    Streubel, Berthold
    Dubsky, Peter
    Gnant, Michael
    Fitzal, Florian
    Zielinski, Christoph C.
    Birner, Peter
    BREAST, 2014, 23 (05) : 637 - 643
  • [4] A prospective study to assess the clinical utility of serum HER2 extracellular domain in breast cancer with HER2 overexpression
    Reix, Nathalie
    Malina, Charlotte
    Chenard, Marie-Pierre
    Bellocq, Jean-Pierre
    Delpous, Stephanie
    Moliere, Sebastien
    Sevrin, Anthony
    Neuberger, Karl
    Tomasetto, Catherine
    Mathelin, Carole
    BREAST CANCER RESEARCH AND TREATMENT, 2016, 160 (02) : 249 - 259
  • [5] HER2 overexpression in metastatic breast cancer: development of therapies
    Pivot, X.
    Jary, M.
    Dobi, E.
    Bazan, F.
    Chaigneau, L.
    Cals, L.
    Almotlak, H.
    Montcuquet, P.
    Meneveau, N.
    Villanueva, C.
    ONCOLOGIE, 2012, 14 (01) : 37 - 40
  • [6] Clinical Relevance of HER2 Overexpression/Amplification in Patients With Small Tumor Size and Node-Negative Breast Cancer
    Curigliano, Giuseppe
    Viale, Giuseppe
    Bagnardi, Vincenzo
    Fumagalli, Luca
    Locatelli, Marzia
    Rotmensz, Nicole
    Ghisini, Raffaella
    Colleoni, Marco
    Munzone, Elisabetta
    Veronesi, Paolo
    Zurrida, Stefano
    Nole, Franco
    Goldhirsch, Aron
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (34) : 5693 - 5699
  • [7] HER2 Expression in Breast Cancer With Nonamplified HER2 and Gains of Chromosome 17 Centromere
    Panvichian, Ravat
    Tantiwetrueangdet, Anchalee
    Wongwaisayawan, Sansanee
    Nampoon, Amporn
    Lertsithichai, Panuwat
    Leelaudomlipi, Surasak
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2012, 20 (04) : 367 - 374
  • [8] Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
    Horimoto, Yoshiya
    Ishizuka, Yumiko
    Ueki, Yuko
    Higuchi, Toru
    Arakawa, Atsushi
    Saito, Mitsue
    BMC CANCER, 2022, 22 (01)
  • [9] HER2 Signaling in Breast Cancer
    Shin, Incheol
    TRANSLATIONAL RESEARCH IN BREAST CANCER, 2021, 1187 : 53 - 79
  • [10] Treatment of HER2 positive breast cancer patients
    Matos, Erika
    ZDRAVNISKI VESTNIK-SLOVENIAN MEDICAL JOURNAL, 2012, 81 (03): : 236 - 245